Current Report Filing (8-k)
July 26 2019 - 4:55PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 22, 2019
Diplomat Pharmacy, Inc.
(Exact Name of Registrant as Specified in its Charter)
|
Michigan
|
|
001-36677
|
|
38-2063100
|
|
(State or Other Jurisdiction of
|
|
(Commission File Number)
|
|
(IRS Employer
|
|
Incorporation)
|
|
|
|
Identification No.)
|
4100 S. Saginaw St.
Flint, Michigan 48507
(Address of Principal Executive Offices) (Zip Code)
(888) 720-4450
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, no par value per share
|
|
DPLO
|
|
New York Stock Exchange
|
Item 3.02 Unregistered Sales of Equity Securities.
On July 22, 2019, in connection with the closing of an acquisition of an infusion pharmacy, Diplomat Pharmacy, Inc. (the “Company”) issued 836,431 shares of its common stock to the former owner of the acquired company. No cash proceeds were received by the Company as the shares represent a portion of the consideration for the acquisition. The 836,431 shares of common stock of the Company issued to the seller in connection with the acquisition were issued and sold pursuant to exemptions from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and/or Rule 506 of Regulation D promulgated thereunder by the Securities and Exchange Commission.
2
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
Diplomat Pharmacy, Inc.
|
|
|
|
|
|
|
|
|
By:
|
/s/ Brian Griffin
|
|
|
|
Brian Griffin
|
|
|
|
Chief Executive Officer
|
Date: July 26, 2019
3
Diplomat Pharmacy (NYSE:DPLO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Diplomat Pharmacy (NYSE:DPLO)
Historical Stock Chart
From Sep 2023 to Sep 2024
